Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Irinotecan Liposome (Onivyde) for Metastatic Pancreatic Cancer
(Open for Input on Submission until May 11, 2017)

RFA: Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma
(Open for Input on Request for Advice until May 2, 2017)

Carfilzomib (Kyprolis) for Multiple Myeloma (relapsed)
(Notification to Implement Issued as of April 17, 2017)

Vandetanib (Caprelsa) for Medullar Thyroid Cancer
(Notification to Implement Issued as of April 17, 2017)

 

Find a Drug Review